|
시장보고서
상품코드
2058272
호흡기 감염 치료 시장 : 약물 종류별, 적응증별, 유통 채널별, 지역별Respiratory Tract Infection Treatment Market, By Drug Class, By Disease Indication, By Distribution Channel, By Geography |
||||||
호흡기 감염 치료 시장은 2026년에 495억 달러로 추정되며, 2033년까지 768억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 6.5%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 495억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 6.50% | 2033년 시장 규모 예측: | 768억 달러 |
호흡기 감염증이란 코, 코 주변의 부비동, 목(인두), 성대(후두), 기관, 기도(기관지) 또는 폐에서 발생하는 모든 감염증을 말하며, 보통 감기로 시작되어 언제든지 발병할 가능성이 있습니다. 이 감염증은 보통 세균이나 바이러스에 의해 발생합니다. 바이러스성 호흡기 감염증은 전염성이 강해 매우 쉽게 전파되는 반면, 세균성 감염증도 상기도 감염증의 경과 중에 발병할 수 있습니다. 호흡기 감염증은 일반적으로 상기도 감염증(코, 목, 인두의 감염증)과 하기도 감염증(후두 아래의 감염증)이라는 두 가지 범주로 분류됩니다.
시장 역학
전 세계 호흡기 감염증 시장은 폐 질환 유병률 증가, 고령 인구 급증, 소아의 폐렴 위험 상승 등의 요인으로 인해 큰 성장이 예상됩니다. 세계보건기구(WHO)에 따르면, 호흡기세포융합바이러스(RSV)는 전 세계 소아에서 발생하는 약 3,000만 건의 하기도 감염의 원인이 되고 있습니다. 이러한 바이러스성 질환의 유병률은 예측 기간 동안 세계 시장의 성장을 견인할 것으로 예상됩니다.
대기 오염의 증가는 어린이뿐만 아니라 성인의 호흡기 건강에도 심각한 영향을 미칠 수 있습니다. 다양한 연구에 따르면, 대기 오염이 천식, COPD(만성 폐쇄성 폐질환), 상기도 알레르기 등 기존의 호흡기질환을 악화시킬 가능성이 있는 것으로 나타났습니다.
그러나 호흡기 감염증 환자에게 NSAIDs나 항생제를 투여할 경우 발생하는 부작용이 시장 성장을 저해할 가능성이 있습니다. 2015년, 미국 식품의약국(FDA)은 심장마비 및 뇌졸중 위험이 높아진다는 점을 강조하기 위해 일반의약품인 NSAIDs의 경고 문구를 강화했습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 호흡기 감염 치료 시장의 주요 기업 개요을 작성했습니다. 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 사항 및 전략입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 정부 주도의 정책, 기술 업그레이드, 시장 확대 및 마케팅 전략과 관련하여 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 호흡기 감염 치료 시장' 보고서는 투자자, 제품 제조사, 호흡기 감염 치료 시장의 유통업체 및 공급업체, 조사·컨설팅 회사, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 호흡기 감염 치료 시장 : 약물 종류별, 2021-2033년
제5장 세계의 호흡기 감염 치료 시장 : 질환 적응증별, 2021-2033년
제6장 세계의 호흡기 감염 치료 시장 : 유통 채널별, 2021-2033년
제7장 세계의 호흡기 감염 치료 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSMRespiratory Tract Infection Treatment Market is estimated to be valued at USD 49.5 Bn in 2026 and is expected to reach USD 76.80 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 49.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.50% | 2033 Value Projection: | USD 76.80 Bn |
Respiratory tract infection is any infection in the nose, sinuses around the nose, throat (pharynx), voice box (larynx), and windpipe (trachea), airways (bronchi) or lungs, which may occur anytime, usually beginning with cold. This infection is usually caused by bacteria and viruses. Virus prone respiratory tract infection are easily transmitted and very contagious while bacterial infection can also be developed during the course of an upper respiratory tract infection. Respiratory tract infection is generally divided into two categories- upper respiratory tract infection (infection in nose, throat, and pharynx) and lower respiratory tract infection (infection below the larynx).
Market Dynamics
The global respiratory tract infection market is expected to witness lucrative growth due to factors such as increasing prevalence of lung diseases, surge in geriatric population, and rising risk of pneumonia in children. According to the World Health Organization (WHO), respiratory syncytial virus (RSV) is responsible for around 30 million lower respiratory tract infection cases in children worldwide. The prevalence of such viral diseases is expected to drive growth of the global market over the forecast period.
Increasing air pollution can severely affect respiratory health of children as well as adults. Various studies have shown effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies.
However, adverse effects of using NSAIDs and antibiotics on patients suffering from respiratory tract infection may hinder growth of the market. In 2015, the U.S. Food and Drug Administration (FDA) increased the warning labels on over-the-counter NSAIDs to highlight elevated risks for heart attack and stroke.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global respiratory tract infection treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global respiratory tract infection treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for respiratory tract infection treatment market, research and consulting firms, new entrants, and financial analysts
Market Segmentation
- By Drug Class (Revenue, USD Bn, 2021-2033)
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Cough Suppressant
- Nasal Decongestant
- Others
- By Disease Indication (Revenue, USD Bn, 2021-2033)
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Abbott Laboratories
- AstraZeneca, Plc
- Abbvie Inc.
- Boehringer Ingelheim GmbH
- Cipla Pharmaceutical Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Merck & Co.
- Novartis AG
- Hoffman La Roche Ltd
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Respiratory Tract Infection Treatment Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Cough Suppressant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Nasal Decongestant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Respiratory Tract Infection Treatment Market, By Disease Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Upper Respiratory Tract Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Lower Respiratory Tract Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Respiratory Tract Infection Treatment Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Respiratory Tract Infection Treatment Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AstraZeneca, Plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Abbvie Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cipla Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline Plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- F. Hoffman La Roche Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
- Abbott Laboratories
9. Section
- References
- Research Methodology
- About Us
